Epitope-based approach for allergy treatments and inhibitors for Crohn's disease
The present disclosure relates to pharmaceutical compounds and compositions and methods for treating an allergy and Crohn's disease. Methods for treating an allergy can include (a) predicting potential epitopes based proteomes of microbiome and that of an allergen, (b) filtering the potential epitopes obtained in step a) to result in a list of epitopes; and (c) reengineering the list of epitopes obtained in step b) to result in the new epitope. Methods for treating Crohn's disease can include (a), identifying one or more binding regions of an HLA class II protein and/or hemagglutinin to I2 superantigen; (b) determining a first peptide sequence corresponding to the one or more binding regions, and (c) producing a peptide inhibitor having a second peptide sequence that is a mutation of the first peptide sequence, wherein the second peptide sequence has a stronger binding affinity to the I2 superantigen than the first peptide sequence.
1 . A peptide comprising a sequence of X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 (SEQ ID NO: 1); wherein:
X 1 is E;
X 2 is T;
X 3 is Q or P;
X 4 is G;
X 5 is A or W;
X 6 is I;
X 7 is V;
X 8 is T;
X 9 is V;
X 10 is K;
X 11 is G or Q;
X 12 is G;
X 13 is L;
X 14 is R; and
X 15 is I, H or W.
2 . A pharmaceutical composition comprising the peptide of claim 1 .
3 . The peptide of claim 1 , wherein X 3 is Q.
4 . The peptide of claim 1 , wherein X 3 is P.
5 . The peptide of claim 1 , wherein X 5 is A.
6 . The peptide of claim 1 , wherein X 5 is W.
7 . The peptide of claim 1 , wherein X 11 is G.
8 . The peptide of claim 1 , wherein X 11 is Q.
9 . The peptide of claim 1 , wherein X 15 is I.
10 . The peptide of claim 1 , wherein X 15 is H.
11 . The peptide of claim 1 , wherein X 15 is W.
12 . The peptide of claim 1 , wherein X 3 is P, X 5 is W, X 11 is Q and X 15 is H.